Introduction
The prognosis of patients with unresectable gastric cancer is poor. To prolong their survival, chemotherapy followed by curative resection has been proposed [1] . To date, intensive intravenous chemotherapy has been employed as the neoadjuvant chemotherapy [2] [3] [4] [5] [6] [7] . However, some patients cannot undergo surgery because of severe toxicity of the chemotherapy or because of tumor progression [2] [3] [4] [5] [6] [7] . A high response rate with distal gastrectomy at a normal bulbus with D2 lymph node dissection, without the resection of any other organ. Macroscopically, ulcer scars were observed in the antrum (Fig. 3) . On microscopic examination, a few tumor cells were detected in the ulcer scar of the resected stomach and in the regional lymph nodes (Fig.  4 ). There were no tumor cells on the surgical margins of the resected specimens. Final findings showed that the tumor was stage IIIb, P0, H0, T3, N2 [8] . No postsurgical complications were observed.
Four months after surgery, the patient is alive without recurrence. He is receiving adjuvant chemotherapy with TS-1, as an outpatient, and has developed no adverse reactions. After treatment (C, D) only the gastric ulcer scar was demonstrated treatment was performed at the outpatient clinic. Endoscopy and upper gastrointestinal tract series revealed gastric ulcer scars (Fig. 1C,D) . On the abdominal CT scan after treatment, the invasion to the duodenum had become unclear, and the regional lymph node had decreased in size (Fig. 2B) .
Three weeks after the completion of the chemotherapy, the patient was operated on. Soft induration due to fibrosis was palpable on part of the bulbar wall of the duodenum. Neither invasion nor adhesion was observed between the primary tumor and the pancreas or the transverse colon. Peritoneal lavage cytology demonstrated no cancer cells in the abdominal cavity. The patient underwent curative resection, consisting of From the preoperative evaluations we diagnosed that the tumor was cStage IV, cP0, cH0, cT4, cN2. The prognosis of patients at stage IV was reported to be extremely poor [9] . Even after resection for cure, there were only a few survivors. To overcome this difficult problem, several investigators have employed pancreaticoduodenectomy for advanced gastric cancer invading the pancreas or duodenum, and some therapeutic effects have been reported [10] [11] [12] . However, there were few survival benefits for those patients with tumors with distant lymph node metastases, because such tumors had already spread to other distant organs or to the peritoneum [10] [11] [12] . Thus, extended surgery alone is not sufficient, and a new strategy has to be considered for these tumors. One possible approach may be neoadjuvant chemotherapy. As a pilot study, we treated this patient with TS-1 preoperatively. Our patient showed surprising reduction of the tumor, without severe toxicity, after chemotherapy with TS-1. TS-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP), and otastat potassium (Oxo) in a molar ratio of 1 : 0.4 : 1, based on the biochemical modulation of 5-fluorouracil (5-FU) [13] . CDHP inhibits dihydropyrimidine dehydrogenase (DPD), an enzyme which degrades 5-FU, and maintains prolonged 5-FU concentrations in the blood and tumors [14] . Oxo is distributed in the gastrointestinal tract at a high concentration after oral administration, and alleviates the gastrointestinal toxicity of 5-FU [15] . TS-1 improves the tumor-selective toxicity of 5-FU, by the actions of the two modulators, CDHP and Oxo. The response rate of TS-1 was reported to be 54% in an early phase II study [16] and 49% and 44% in late phase II studies [17, 18] . In these reports, major adverse reactions were gastrointestinal symptoms and myelosuppression, with little severe toxicity [16] [17] [18] . The results suggested that TS-1 was suitable for outpatients because of its mild toxicity and high response rate [17, 18] .
In a setting of neoadjuvant chemotherapy, the regimen used should not induce severe toxicity that may delay surgery, while it should induce a high response rate, to improve the resectability of the tumor. To date, several intensive intravenous chemotherapeutic regimens, including EAP, FLP, FLEP, and PMUE, have been used as neoadjuvant chemotherapy [2] [3] [4] [5] [6] [7] . Intensive chemotherapy usually requires hospital care, because of its serious side effects, resulting in an impaired quality of life. It was reported that some patients who received neoadjuvant chemotherapy could not undergo surgical resection because of severe toxicity or tumor progression [2] [3] [4] [5] [6] [7] . Until TS-1 was developed, there was no oral agent with a high response rate and acceptable toxicities.
As demonstrated in this case report, our patient was treated with TS-1, as an outpatient, and TS-1 induced dramatic reduction of the tumor, without serious toxicity. Moreover, operation was not delayed and no surgical complications were observed. Our report is the first to demonstrate the advantages of TS-1 as neoadjuvant chemotherapy for the treatment of advanced gastric carcinoma. 
